Adding focused radiation to standard treatment for recurrent ovarian cancer

Plain-English translation of NCT05444270 on ClinicalTrials.gov ↗ · Source last updated November 2023 · Translation generated July 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing whether combining standard salvage chemotherapy with a specialized radiation technique called stereotactic ablative radiotherapy (SABR) works better than chemotherapy alone for ovarian cancer that has returned after initial treatment. SABR is a type of focused radiation that delivers high doses of radiation very precisely to tumors while minimizing exposure to nearby healthy tissue. About half of participants will receive chemotherapy only, while the other half will receive chemotherapy plus SABR targeted at the recurrent cancer sites.

When ovarian cancer comes back after initial treatment, doctors need better options to help patients live longer and better. Researchers believe that combining chemotherapy with this specialized radiation technique might help destroy cancer that has spread to multiple sites throughout the body more effectively than chemotherapy alone.

Do you qualify?

You likely qualify if…

you have been diagnosed with epithelial ovarian cancer that has come back after your initial treatment
you have completed standard treatment (surgery and chemotherapy) for your ovarian cancer
you have 10 or fewer areas of recurrent cancer, each measuring 5 centimeters or smaller
you are at least 19 years old
your bone marrow, heart, and overall health are stable enough to tolerate the treatment, as confirmed by recent blood tests and medical evaluation

You likely don't qualify if…

you have cancer that has spread to your brain
you have widespread cancer throughout your abdominal lining
you have fluid around your heart or lungs that contains cancer cells
you have had radiation therapy to these recurrent cancer sites before
you are pregnant or have had other invasive cancers within the past 3 years (with some exceptions)

What participation looks like

If you enroll, you'll be randomly assigned to one of two groups: one receiving standard chemotherapy alone, or one receiving standard chemotherapy plus the specialized radiation therapy. You'll have regular check-up visits at 3, 6, 9, 12, 18, 24, 30, and 36 months after treatment ends, which will include physical exams, blood tests, and imaging scans to monitor how well the treatment is working and watch for any side effects. You'll also complete questionnaires about your quality of life at certain time points during the study.

AI-generated summary from trial data · Jul 15, 2026 · Not medical advice

Trial locations(1 site)

South Korea

Yonsei University Health System, Severance Hospital, Seoul